AKT1 and endometrioid adenocarcinoma: AKT1 actionability was 22, 45 and 35% in patients with high-grade serous, endometrioid and clear cell carcinomas, respectively, and AKT1 alterations were observed in 14–18% of patients with serous and endometrioid carcinomas.